We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Shire Pharmaceuticals remains committed to protecting the patents which it has
relating to Adderall XR, its product for treatment of attention-deficit/hyperactivity
disorder (ADHD).
An Australian biotech company has acquired Myomatrix
Therapeutics of Rensselaer, N.Y. Terms of the deal were not disclosed. Cytopia
Inc., a wholly owned subsidiary of Cytopia Ltd., plans to add staff once the
merger is completed. Shreefal Mehta, Myomatrix CEO, will be vice president of
the merged entity.
It would be a mistake to remove the FDA's drug safety office from the agency
as a way to ensure total independence from the new drug office, says an industry
expert who cautioned the FDA and lawmakers not to overreact to recent adverse
events surrounding Cox-2 inhibitors.
Several prominent Democrats have sent a letter to the Government Accountability Office (GAO) asking the watchdog agency to examine "covert propaganda" being employed by the Bush administration, including actions related to the Medicare Modernization Act (MMA).
Wyeth has agreed to support an amendment to a nationwide
legal settlement with users of its fen-phen products -- a move that would guarantee
payments to the largest group of members involved in the class action lawsuit.
Spending growth for prescription drugs in the U.S. decelerated at a rapid rate
in 2003, according to new data released by the Centers for Medicare & Medicaid
Services (CMS).
Alltracel Pharmaceuticals has announced that following the successful EGM and
re-admission of the company's enlarged issued share capital to trading on AIM
it has now formally acquired the entire issued share capital of Westone Products,
for a total consideration of up to EUR8m, in a mixed cash and paper offer.
Roche Holding AG has won European Union approval for its colon cancer treatment
Avastin, which helped drive growth at the Swiss drugmaker last year after sales
got off to a flying start in the U.S. Roche said on Friday that the drug had
been granted marketing approval by EU regulators, as expected, as a first-line
treatment for colon cancer in combination with certain kinds of chemotherapy.
Lasky & Rifkind, a law firm with offices in New York and Chicago, has announced
that a lawsuit has been filed in the United States District Court for the Southern
District of New York, on behalf of persons who purchased or otherwise acquired
publicly traded securities of Atherogenics between Sept. 28, 2004 and Dec. 31,
2004, inclusive.
Kobayashi Pharmaceutical has acquired a sole distributorship for Inochi-No-Haha
A, a special supplement for females manufactured and distributed by Sasaoka
Yakuhin.